Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonates and primary hyperparathyroidism.

Gideon A Rodan1

  • 1Department of Bone Biology and Osteoporosis Research, Merck & Co., West Point, Pennsylvania 19846, USA.

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|November 5, 2002
PubMed
Summary

Bisphosphonates (BPs) effectively inhibit bone resorption by targeting osteoclasts. Studies show BPs treat hypercalcemia of malignancy and can reverse bone loss in primary hyperparathyroidism.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.

Bioorganic & medicinal chemistry letters·2010
Same author

Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands.

The Journal of biological chemistry·2009
Same author

Control of rat tail skin temperature regulation by estrogen receptor-beta selective ligand.

Maturitas·2009
Same author

Agonist-like SERM effects on ERalpha-mediated repression of MMP1 promoter activity predict in vivo effects on bone and uterus.

The Journal of steroid biochemistry and molecular biology·2008
Same author

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

Bioorganic & medicinal chemistry letters·2008
Same author

Involvement of alpha(v)beta3 integrins in osteoclast function.

Journal of bone and mineral metabolism·2007

Area of Science:

  • Biochemistry
  • Endocrinology
  • Pharmacology

Background:

  • Bisphosphonates (BPs) are potent inhibitors of bone resorption.
  • They function by inhibiting farnesyl diphosphate synthase, leading to osteoclast inactivation.
  • BPs are indicated for conditions involving excessive bone loss.

Purpose of the Study:

  • To evaluate the efficacy of bisphosphonates in managing hypercalcemia of malignancy (MIH).
  • To assess the potential of bisphosphonates in reversing bone loss associated with primary hyperparathyroidism (PHPT).

Main Methods:

  • Review of existing data on bisphosphonate use in hypercalcemia and hyperparathyroidism.
  • Analysis of bisphosphonate mechanism of action on osteoclasts.

Main Results:

Related Experiment Videos

  • Bisphosphonates are the treatment of choice for malignancy-induced hypercalcemia at higher doses.
  • Evidence suggests that bisphosphonates at osteoporosis-relevant doses can reverse bone loss in mild PHPT.

Conclusions:

  • Bisphosphonates are effective in managing hypercalcemia of malignancy.
  • Bisphosphonates show promise in treating bone loss associated with primary hyperparathyroidism.